Breaking News

You are here » Indian-Commodity  :  Commodities  :  Turmeric  :  Turmeric futures trade lower on profit booking

09-Aug2018

Turmeric futures trade lower on profit booking

Turmeric futures trade lower on NCDEX, due to profit-taking by investors amid expectations of higher acreage of turmeric in Andhra Pradesh and Maharashtra following good rains this monsoon. Meanwhile, poor exports and domestic demand also dragged the prices down.

The contract for August delivery was trading at Rs 7176.00, down by 0.47% or Rs 34.00 from its previous closing of Rs 7210.00. The open interest of the contract stood at 6230 lots.

The contract for September delivery was trading at Rs 7250.00, down by 0.06% or Rs 4.00 from its previous closing of Rs 7254.00. The open interest of the contract stood at 16520 lots on NCDEX.


Related News

View all news

Turmeric futures trade lower on improved crop prospects

Turmeric futures traded lower on NCDEX, due to trimming of bets by market players on the back of improved crop prospects in Maharashtra. Further, expectation of fresh arrivals at the spot market amid sufficient......

Turmeric futures trade mixed on NCDEX

Turmeric futures traded mixed on NCDEX, as contract for April traded up on the back of concerns that drought conditions and cold weather will affect the crop production, while contract for May traded down......

Turmeric futures trade lower on NCDEX

Turmeric futures traded lower on NCDEX, on the back of improved crop prospects in Maharashtra. Further, expectation of higher production this season due to higher acreage in Telangana also fuelled the......

Top News

View all news

Tata Motors signs LTS agreement with its employees

Tata Motors has signed a long-term wage settlement (LTS) agreement with its employees. Under the agreement, workmen will get a wage rise of Rs 9,000 per month along with other incentives based on performance.......

Canara Bank invites bids from merchant bankers to manage its $350-500 million MTN issue: Report

Canara Bank has reportedly invited bids from merchant bankers to manage its $350-500 million issue of senior unsecured/tier-II capital bonds under its medium-term note (MTN) programme. The issue size may......

Alembic Pharma gets USFDA's nod for Acetazolamide Extended-Release Capsules

Alembic Pharmaceuticals (Alembic) has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Acetazolamide Extended-Release Capsules, 500......